⚡ This is your brand? Claim your page FREE and bring it to life on AI search.
AI Visibility Scorecard
IDHIFA®: For Relapsed / Refractory Acute Myeloid Leukemia
idhifa.com · Healthcare
Somewhat visible. AI bots can read IDHIFA®: For Relapsed / Refractory Acute Myeloid Leukemia, but it is missing the structured signals that push citation rate above competitors.
AI engines read this profile 4 times
Apple Intelligence · Claude · Meta AI
#168,044 of 839,071 in Healthcare for AI visibility
5.5
/10
AEO Score
About IDHIFA®: For Relapsed / Refractory Acute Myeloid Leukemia
from our crawl and measurement
IDHIFA®: For Relapsed / Refractory Acute Myeloid Leukemia is a business whose own site puts it this way: "IDHIFA® (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as." Its AI visibility score is 5.5 out of 10: the engines can find it, but they do not have much to hold on to.
Our crawl found structured data on the page (Drug, TherapeuticProcedure, MedicalAudience) and a sitemap. It is missing an llms.txt file and a heading structure that lays out what it offers.
AI crawlers have visited 2 times in our tracking, including ClaudeBot (Anthropic) and Applebot (Siri).
The 6 signals AI reads
Higher is better · 0-10
Structured Data
3
Organization / LocalBusiness JSON-LD that AI can read.
Content Structure
8
Clear headings and answer-style content.
Entity Clarity
4
How clearly your brand identity reads to AI.
E-E-A-T Signals
Experience, Expertise, Authority, Trust
3
Experience, Expertise, Authority, Trust markers.
Technical AEO
7
robots.txt, llms.txt, and AI-bot crawl access.
AI Discoverability
6
Sitemaps and entity links AI can follow.
Off-page authority
How the web signals your brand to AI
Backlinks
9
Inbound links from other sites.
Domain Authority
1
Established authority for your domain.
Reference Presence
0
Not in AI knowledge graphs yet.
News & Press
0
No press coverage found yet.
Community
0
No community discussion yet.
Social Mentions
0
No social discussion found yet.
What this score means
Your AEO score measures whether AI search engines - ChatGPT, Claude, Perplexity, Gemini - can actually read your site and cite it in answers. Roughly two-thirds of sites are invisible to them. At 5.5/10, IDHIFA®: For Relapsed / Refractory Acute Myeloid Leukemia has a working base to build on - fixable, and the signals above are where to start.
Is this your brand?
The exact fixes for IDHIFA®: For Relapsed / Refractory Acute Myeloid Leukemia
Which AI engines already crawl you
Weekly ChatGPT & Claude citation tracking
How to Get Your Brand Cited by ChatGPT, Gemini, and Claude: The Complete AEO Guide
The search landscape has fundamentally shifted. While Google still dominates, millions of users now ask questions to ChatGPT, Gemini, and Claude instead of typing into a search bar.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for IDHIFA®: For Relapsed / Refractory Acute Myeloid Leukemia.
Source & Attribution
Scored by Engagemii on August 7, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/idhifa
Cite this score: Engagemii (2026). "AEO Score for IDHIFA®: For Relapsed / Refractory Acute Myeloid Leukemia." Retrieved from https://engagemii.com/aeo/brands/idhifa
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - The Answer Engine Optimization (AEO) Platform